These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
283 related articles for article (PubMed ID: 31639332)
1. BRAF V600E mutations are not an oncogenic driver of solitary xanthogranuloma and reticulohistiocytoma: Testing may be useful in screening for Erdheim-Chester disease. Hoyt BS; Yan S; Linos KD; Momtahen S; Sriharan A; Tran TN; Tsongalis GJ; O'Meara RR; Green DC; LeBlanc RE Exp Mol Pathol; 2019 Dec; 111():104320. PubMed ID: 31639332 [TBL] [Abstract][Full Text] [Related]
2. BRAF V600E mutation in Juvenile Xanthogranuloma family neoplasms of the central nervous system (CNS-JXG): a revised diagnostic algorithm to include pediatric Erdheim-Chester disease. Picarsic J; Pysher T; Zhou H; Fluchel M; Pettit T; Whitehead M; Surrey LF; Harding B; Goldstein G; Fellig Y; Weintraub M; Mobley BC; Sharples PM; Sulis ML; Diamond EL; Jaffe R; Shekdar K; Santi M Acta Neuropathol Commun; 2019 Nov; 7(1):168. PubMed ID: 31685033 [TBL] [Abstract][Full Text] [Related]
3. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Haroche J; Charlotte F; Arnaud L; von Deimling A; Hélias-Rodzewicz Z; Hervier B; Cohen-Aubart F; Launay D; Lesot A; Mokhtari K; Canioni D; Galmiche L; Rose C; Schmalzing M; Croockewit S; Kambouchner M; Copin MC; Fraitag S; Sahm F; Brousse N; Amoura Z; Donadieu J; Emile JF Blood; 2012 Sep; 120(13):2700-3. PubMed ID: 22879539 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of clinicopathologic characteristics and the BRAF V600E mutation in Erdheim-Chester disease among Chinese adults. Cao XX; Sun J; Li J; Zhong DR; Niu N; Duan MH; Liang ZY; Zhou DB Ann Hematol; 2016 Apr; 95(5):745-50. PubMed ID: 26858028 [TBL] [Abstract][Full Text] [Related]
5. Langerhans cell histiocytosis and Erdheim-Chester disease, both with cutaneous presentations, and papillary thyroid carcinoma all harboring the BRAF(V600E) mutation. Johnson WT; Patel P; Hernandez A; Grandinetti LM; Huen AC; Marks S; Ho J; Monaco SE; Jaffe R; Picarsic J J Cutan Pathol; 2016 Mar; 43(3):270-5. PubMed ID: 26454140 [TBL] [Abstract][Full Text] [Related]
6. Hypoalphalipoproteinemia and BRAF Cohen-Aubart F; Guerin M; Poupel L; Cluzel P; Saint-Charles F; Charlotte F; Arsafi Y; Emile JF; Frisdal E; Le Goff C; Donadieu J; Amoura Z; Lesnik P; Haroche J; Le Goff W Arterioscler Thromb Vasc Biol; 2018 Aug; 38(8):1913-1925. PubMed ID: 29930009 [TBL] [Abstract][Full Text] [Related]
7. Abdominal involvement in Erdheim-Chester disease (ECD): MRI and CT imaging findings and their association with BRAF Nikpanah M; Kim L; Mirmomen SM; Symons R; Papageorgiou I; Gahl WA; O'Brien K; Estrada-Veras JI; Malayeri AA Eur Radiol; 2018 Sep; 28(9):3751-3759. PubMed ID: 29556768 [TBL] [Abstract][Full Text] [Related]
8. Thoracic involvement in Erdheim-Chester disease: computed tomography imaging findings and their association with the BRAF Mirmomen SM; Sirajuddin A; Nikpanah M; Symons R; Paschall AK; Papageorgiou I; Gahl WA; O'Brien K; Estrada-Veras JI; Malayeri AA Eur Radiol; 2018 Nov; 28(11):4635-4642. PubMed ID: 29736852 [TBL] [Abstract][Full Text] [Related]
13. BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease. Janku F; Vibat CR; Kosco K; Holley VR; Cabrilo G; Meric-Bernstam F; Stepanek VM; Lin PP; Leppin L; Hassaine L; Poole JC; Kurzrock R; Erlander MG Oncotarget; 2014 Jun; 5(11):3607-10. PubMed ID: 25003820 [TBL] [Abstract][Full Text] [Related]
14. The clinical spectrum and prognostic factors of Erdheim-Chester disease and mixed Langerhans cell histiocytosis and Erdheim-Chester disease. Dai JW; Lin H; Chang L; Li J; Zhou DB; Cao XX Ann Hematol; 2023 Dec; 102(12):3335-3343. PubMed ID: 37922006 [TBL] [Abstract][Full Text] [Related]
15. Young JR; Johnson GB; Murphy RC; Go RS; Broski SM J Nucl Med; 2018 May; 59(5):774-779. PubMed ID: 29097410 [TBL] [Abstract][Full Text] [Related]
16. Successful treatment with cladribine of Erdheim-Chester disease with orbital and central nervous system involvement developing after treatment of Langerhans cell histiocytosis. Perić P; Antić B; Knezević-Usaj S; Radić-Tasić O; Radovinović-Tasić S; Vasić-Vilić J; Sekulović L; Tarabar O; Tukić L; Jovandić S; Magić Z Vojnosanit Pregl; 2016 Jan; 73(1):83-7. PubMed ID: 26964390 [TBL] [Abstract][Full Text] [Related]
17. Does the BRAF(V600E) mutation herald a new treatment era for Erdheim-Chester disease? A case-based review of a rare and difficult to diagnose disorder. Bosco J; Allende A; Varikatt W; Lee R; Stewart GJ Intern Med J; 2015 Mar; 45(3):348-51. PubMed ID: 25735579 [TBL] [Abstract][Full Text] [Related]
18. Dramatic efficacy of dabrafenib in Erdheim-Chester disease (ECD): a pediatric patient with multiple large intracranial ECD lesions hidden by refractory Langerhans cell histiocytosis. Hao X; Feng R; Bi Y; Liu Y; Li C; Lu T; Tian Y J Neurosurg Pediatr; 2019 Jan; 23(1):48-53. PubMed ID: 30265230 [TBL] [Abstract][Full Text] [Related]